Human influenza hemagglutinin (HA) is a type of glycoprotein responsible for initiation of virus infections in the human body. Therefore, inhibition of hemagglutinin is important to prevent contagious respiratory illness caused by the influenza virus. Anti-HA antibody is used to prevent the virus from binding with host cells in the body and infecting. Anti-HA antibody plays a key role in neutralizing virus that can cause epidemic and pandemic influenza.
Anti-HA antibody facilitates functions like immunoprecipitation, western blot, and indirect immunofluorescence to fight the influenza virus. According to the CDC, it is estimated that the influenza virus has resulted in approximately 35 million cases of illness between 2018 to 2019 in the U.S.
Covid-19 pandemic has reduced and delayed physician visits and hospitalization rate and is expected to reduce the demand of anti-HA antibody for short-term. However, this is expected to balance in long term scenario and growth trends will remains positive for the next decade. Manufacturing and supply chain activities of anti-HA antibody market are expected to hamper due to nation-wide lockdown situation across the majority of countries in the world amid Covid-19 pandemic.
The rise in prevalence of influenza infections is expected to drive anti-HA antibody market growth. With an increase in research and development activities for the anti-HA antibody, the leading industry players are investing in the anti-HA antibody market. For instance, in March 2020 Duke Human Vaccine Institute was awarded US$400 million federal grants for consecutive seven years by National Institute of Allergy and Infectious Diseases (NAID) for development of universal flu vaccine.
Increasing awareness and treatment seeking rate of influenza infection are expected to boost anti-HA antibody market growth. Stringent regulatory requirements for approval of drugs can hinder anti-HA antibody market growth.
Find Out More about the Report Coverage
|Based on the type of antibody||
|Based on the application||
|Based on the sales channel||
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Some key players contributing in anti-HA antibody market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Amgen Inc., AbbVie Pharmaceuticals, Eli Lilly and Company, Alexion Pharmaceuticals Inc., GlaxoSmithKline plc., Seattle Genetics, Sanofi S.A., Biogen Inc., AstraZeneca PLC and others.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
The report on anti-HA antibody market covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2015 - 2019
- Market Size & Forecast 2020 to 2030
- Supply & Demand Value Chain
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
- Market Drivers and Restraints
Explore Persistence Market Research’s expertise in promulgation of the business !
Regional analysis for anti-HA antibody market includes
- North America
- Latin America
- East Asia
- South Asia
- Middle East & Africa
Report on anti-HA antibody market highlights:
- Shifting industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size
- Recent industry trends
- Key competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance